Title
Category
Credits
Event date
Cost
Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
08/14/2025
$0.00
With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.